

WFS1 V288G — Wolframin

Valine → Glycine at position 288 in wolframin's N-terminal cytoplasmic domain. ClinVar Likely pathogenic for Wolfram syndrome 1. AlphaMissense 0.480 (below threshold) — AM under-call. DynaMut2 $\Delta\Delta G$ -0.23 kcal/mol. pLDDT 58 borderline.

IDENTITY

Variant	V288G (p.Valine288Glycine)
DNA change	c.863T>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV003767181
Amino acid change	Valine (V) → Glycine (G) — branched aliphatic hydrophobic replaced by smallest amino acid. Loss of side chain entirely.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 288	58.47 CONFIDENT
Domain	N-terminal cytoplasmic domain (87-313)
Position context	N-terminal cytoplasmic domain · position 288 in a borderline-confidence region (pLDDT 58).
IDR flag	No — pLDDT well above 50 threshold

Position 288 sits in wolframin's N-terminal cytoplasmic domain. The AlphaFold model places V288 within 5 Å of VAL289 (2.5 Å), LYS287 (2.5 Å), LEU284 (4.0 Å), ALA295 (4.5 Å), and LEU286 (4.5 Å). Mostly hydrophobic environment. Replacing V288 with glycine removes the branched aliphatic side chain entirely, creating a cavity. The fold absorbs the substitution ($|\Delta\Delta G|$ 0.23 small) — the glycine permits backbone conformations the wild-type valine constrained, possibly compensating somewhat for the lost packing volume. AlphaMissense's 0.480 is below the threshold — AM under-call. ClinVar Likely Pathogenic + Wolfram 1 establishes clinical pathogenicity. pLDDT 58 is borderline; structural details deserve wet-lab confirmation.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE 0.480 am_class: Amb — threshold > 0.564	DYNAMUT2 $\Delta\Delta G$ -0.23 kcal/ mol Destabilising · Job 177992009249	PLDDT (ALPHAFOLD) 58.47 confident
--	---	--

CLINICAL EVIDENCE

ClinVar classification	LIKELY PATHOGENIC
Review status	criteria provided, single submitter
Last evaluated	2024/02/27 00:00
Inheritance	Wolfram syndrome 1 (AR) documented.
WFS1 variant landscape	V288G is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)
	<ul style="list-style-type: none">• Wolfram syndrome 1

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$ 2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable (AM + pLDDT caveats). $|\Delta\Delta G| = 0.23$ — fold survives. AlphaMissense 0.480 below threshold but ClinVar Pathogenic + Wolfram 1.

Mechanism is hydrophobic cavity creation. Therapeutic strategy: wet-lab validation before committing to design.

V288G joins the AM-under-call class. The borderline pLDDT and AM signal together make this a wet-lab-priority variant.